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Abstract
INDUCED-PLURIPOTENT STEM-DERIVED NEURONAL PROGENITOR CELLS
AS A NOVEL TREATMENT FOR NEURODEGENERATIVE DISEASES
Dennisse Andrea Gonzalez-Romero
Supervisory Professor: Claudio Soto, Ph.D.

Cellular therapies, as neuronal progenitor (NP) cells grafting, are promising
therapies for patients affected with neurodegenerative diseases like CreutzfeldtJakob Disease (CJD). At this time there is no effective treatment or cure for CJD.
The disease is inevitably fatal and affected people usually die within months of the
appearance of the first clinical symptoms. Compelling evidence indicate that the
hallmark event in the disease is the conversion of the normal prion protein (termed
PrPC) into the disease-associated, misfolded form (called PrPSc). Thus, a
reasonable therapeutic target would be to prevent PrP misfolding and prion
replication. This strategy has been applied with poor results since at the time of
clinical intervention substantial brain damage has been done. It seems that a more
effective treatment aimed at patients with established symptoms of CJD would need
to stop further brain degeneration or even recover some of the previously lost brain
tissue. The most promising possibility to recover brain tissue is the use of NPs that
have the potential to replenish the nerve cells lost during the early stages of the
disease.
Advanced cellular therapies, beside their potential for cell replacement, might
be used as biomaterials for drug delivery in order to stimulate cell survival or the
resolution the disease. Also, implanted cells can be genetically manipulated to
correct abnormalities causing disease or to make them more resistant to the toxic
microenvironments present in damaged tissue.
In recent years cell engineering has been within the scope of the scientific and
general community after the development of technologies able to “de-differentiate”
somatic cells into induced-pluripotent stem (IPS) cells. This new tool permits the
use of easy-to-reach cells like skin or blood cells as a primary material to obtain
iv

embryonic stem-like cells for cellular therapies, evading all ethical issues regarding
the use of human embryos as a source of embryonic stem cells.
The complete work proposes to implant IPS-derived NP cells into the brain of prioninfected animals to evaluate their therapeutic potential. Since it is well known that
the expression of prion protein in the cell membrane is necessary for PrPSc
mediated toxicity, we also want to determine if NPs lacking the prion protein have
better survival rates once implanted into sick animals.
The main objective of this work is to develop implantable neural precursor
from IPS coming from animals lacking the prion protein.
Specific aim 1: To develop and characterize cellular cultures of IPS cells from
prp-/- mice. Fibroblasts from prp-/- animals will be reprogrammed using the four
Yamanaka factors. IPS colonies will be selected and characterized by
immunohistochemistry for markers of pluripotency. Their developmental capabilities
will be evaluated by teratoma and embryoid body formation assays.
Specific aim 2: To differentiate IPS cells to a neuronal lineage. IPS cells will
be differentiated to a NP stage by the use of defined media culture conditions. NP
cells will be characterized by their immunohistochemical profile as well as by their
ability to differentiate into neuronal cells.
Specific aim 3: Cellular labeling of neuronal progenitors cells for in vitro
traceability. In order to track the cells once implanted in the host brain, they will be
tagged with different methods such as lipophilic fluorescent tracers and transduction
with GFP protein expression.
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I. Introduction
Neurodegenerative diseases (NDs) are a group of brain disorders in which
there is significant neuronal cell loss. Some of the most emblematic examples
include Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), Amyotrophic Lateral
Sclerosis (ALS) and Creutzfeldt-Jakob’s disease (CJD). All those diseases are
mainly manifested in elderly, with the risk increasing exponentially with age. Since
life expectancy has increased substantially in the last century, an epidemic of
neurodegenerative diseases is expected in the coming years. It is estimated that
the number of cases of AD alone will rise from 5.4 million in 2011 to 15 millions in
2050 [1, 2] if no effective therapies become available.
Currently there are no effective treatments for any ND. To date available
therapies only include palliative strategies. This scenario is aggravated by the lack
of early diagnostic tools. For this reason we believe it is necessary to develop new
therapies aimed to recover brain tissue and functionality even after substantial brain
damage is done, which represent the situation when patients are clinically
diagnosed.
Stem cells are at the center of intensive investigation as potential cell
replacement treatment for a wide number of diseases. They have the potential to be
“transformed” into any cell type of the body, being a good biomaterial for the
construction of tissue or even whole organs outside the individual for later
transplantation. Pioneering work was done using human embryonic stem cells taken
from discarded embryos from in vitro fertilization clinics; however the ethical and
legal issues associated with the use of human embryos, in addition to the variable
and sometimes poor quality of the cells, made the use of human embryonic cells
difficult to evaluate their potential in clinical trials. Recently a novel approach is
being explored by many groups worldwide after the outreaching discoveries made
by Yamanaka and Takahashi in 2006. They reprogrammed somatic cells to an
embryonic equivalent stage, which they called induced-pluripotent stem (IPS) cells
[3]. Those cells were shown to have self-renewing and developmental pluripotency
capabilities. This new technology offers opportunities for autologous cell therapies,
1

patient-specific drug screening [4] and the development of new in-vitro models of
diseases, besides overcoming the ethical aspects of using embryonic stem cells.
The next sections will provide an introduction to neurodegenerative diseases,
stem cells and how iPS cells are ideal sources of donor cells for replacement
therapies as well as useful tools for in situ release of trophic factors or drugs.
I.1.1. Molecular mechanism of neurodegenerative diseases
A common characteristic of NDs is the appearance of protein aggregates
(also called amyloids) in the brain parenchyma or inside neuronal cells. The
aggregates are constituted of abnormally folded proteins, which vary according to
the disease[5] . For example, beta-amyloid peptide is the main component of
aggregates (called plaques) in AD; alpha-synuclein in PD; SOD-1, FUS and/or TDP43 in ALS; huntintin in HD or prion protein in CJD.

Regardless of the protein

involved the common pathological event involve the re-folding of the normal host
protein into a stable misfolded variant which can multimerize with units of the same
protein and induce their abnormal reassembly (see box 1). The most current
theories of neurodegeneration propose that small oligomers in their aberrant
conformation are the most toxic particles for cells by many concurrent mechanisms.
For example, studies done in AD suggest that beta-amyloid induce the dysfunction
of synaptic activity at the pre- and postsynaptic levels (reviewed in [6]), calcium
deregulation due to the formation of pores in the plasmatic membranes and
activation of apoptotic pathways. Also, cells experimenting distress due to fibrillar
forms of beta-amyloid peptide or prions activate the unfolded protein response
(UPR) inducing the down down regulation of the general expression of proteins but
overexpression of molecular chaperons leading eventually to apoptotic death (rev in
[7]).

I.1.2. Prion Disorders as a model of Neurodegenerative diseases

2

Prion diseases, also called Transmissible Spongiform Encephalopathies
(TSEs), are a group of fatal progressive neurological disorders affecting humans
and other mammals like deer, sheep, cattle, minks, and others. Human TSEs
include CJD (familial, variant and iatrogenic forms), kuru, fatal familial insomnia and
Gerstmann-Straussler-Scheinker

syndrome.

Clinical

symptoms

are

variable

depending on the disease, but include loss of motor coordination, dementia, ataxia,
vision impairment, and sleep disturbances.

The disease is inevitably fatal and

affected people usually die within months of the appearance of the first clinical
symptoms. At the pathological level, the brain of affected individuals shows
vacuolation, extensive astrogliosis and the accumulation of prion protein
aggregates.
Prion protein is a glycoprotein of around 210 amino acids encoded by a
single gene (prnp). It harbors a glycophosphatidylinositol (GPI) motif that binds to
the external side of the plasma membrane. There are still no clear physiological
functions attributed to the prion protein, however data suggest that might be
participating in cell adhesion, copper uptake, protection against oxidative stress,
modulation of neuronal excitability, regeneration of adult muscle tissue, and
regulation of apoptosis [8-12]. The current model of prion pathogenesis indicates
that the normal host prion protein (called PrPC) converts into a disease-associated
conformation (called PrPSc). In its abnormal conformation PrPSc is able to recruit
PrPC and act as a corrupt template inducing the conversion toward PrPSc
conformation. The dynamic of misfolding follows a seeding-nucleation model of
polymerization, including a slow phase where the primary PrPSc seeds are formed
and a fast phase when the polymerizing events take place to finally form fibrillar
structures of different sizes (see box 1). In vivo, the initial step of PrPSc formation
might be facilitated by mutations that make PrPC prone to misfold and form the
primary seeds; these events could explain the cases of familial prion diseases. Also,
the formation of PrPSc in wild type animals can be induced by the administration of
PrPSc from infected tissues.
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A very important contribution to understanding the mechanism of prion
diseases was made with the development of prion protein knockout mice. Mice
lacking the prion protein were shown to be viable without any dramatic phenotypic
alteration while they were resistant to prion infection. This result strongly suggested
that

PrPC expression is absolutely necessary to develop the disease [13]. In

accordance with this result, the reintroduction of the prion protein in the prp-/- mice
restores the infectivity of PrPSc [14]. Further studies in mice showed that the brain
tissue of prp-/- mice is resistant to PrPSc-mediated toxicity [15]. Furthers studies
also indicated that the prion protein must be attached to the cell membrane in order
for the cells to be susceptible to prion toxicity. Indeed, Chesebro et al. showed that
transgenic animals expressing the prion protein without its GPI anchor do not
develop the clinical disease, but are still able to replicate PrPSc [16]. Similar results
were obtained in vitro where cells expressing the anchorless prion protein were
shown to be resistant to prion infection [17]. Taken together this data supports the
hypothesis that neuronal stem cells lacking the prion protein might be more
resistant to prion toxicity in vivo when implanted into a diseased animal.
Many lines of evidence suggest that other NDs follow a prion-like mechanism
of protein misfolding [18]. For example there is substantial evidence suggesting that
beta-amyloid peptide misfolds following the same kinetics as prions and that it could
be also transmissible between individuals [19-21] as well as between neurons.
Similar findings have been published suggesting that ALS [22] and Parkinson’s
might follow the same mechanism. An interesting example of prion-like spreading of
misfolded proteins was observed in postmortem analysis of Parkinson brains that
were grafted with healthy embryonic neurons.

A subset of the implanted cells

harbored Lewy bodies (aggregates mainly composed of alpha-synuclein),
suggesting that the misfolding events took place after the cells were in contact with
the misfolded alpha-synuclein seeds present in the Parkinsonian brain [23-25].
Further experiments showed that alpha-synuclein is internalized by neuronal stem
cells when they are implanted in an animal model of Parkinson’s[26], suggesting a
cell to cell transmission of the oligomeric, misfolded particles.

4

Box1. Kinetics of prion-like protein misfolding. Proteins showing high
tendency to self aggregation in a prion
prion-like
like fashion contain hydrophobic motifs that
tend to self-interact
interact forming unstable intermediate isoforms (1). When a critical
number of monomers interact forming a stable seed (2),

the misfolding
misfo
process

accelerates exponentially (3) until the majority of the native protein has been
converted to the abnormal conformation (4).

I.1.3 Therapeutic alternatives for protein misfolding disorders
The most promising treatments against neurodegenerat
neurodegenerative
ive disorders target
the protein misfolding process
process.. Along these lines pioneering work headed by Dr.
Soto showed that beta-sheet
sheet breaker (BSB) peptides, (short peptides with high
homology to amyloidogenic regions of fibrillogenic proteins but harboring proline
pro
as
beta-sheet destabilizing residues
residues),, are able to avoid the formation of amyloid fibrils
and re-dissolve
dissolve existing ones. BSBs designed for beta
beta-amyloid
amyloid peptide and prions
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were shown to be effective in vitro and in vivo [27-30]. However, due to their
peptidic nature, they were extremely labile when administered systemically. We
believe that BSB, secreted from grafted cells, can be a useful tool to fight the
formation of amyloid deposits already existing in the brain, as well as to help stop
the misfolding of new proteins.

I.2.1. Stem cells
Stem cell is the general term to describe self-renewing cells able to
differentiate to many specific cellular types. Embryonic stem cells (ESC) are present
in the inner mass of the blastocyst and can give rise to any embryonic tissue,
therefore called “pluripotent cells”. Adult tissue harbors “adult stem cells” which are
progenitor cells able to give raise to a restricted spectrum of cell types, hence called
“multipotent” progenitors cells.
For more than five decades researchers have tried to generate pluripotent
cells from somatic cells. The first “cloning” technology was described by King and
Brigs in the 1950’s; they and others showed that by transferring the nuclei of a latestage embryonic cell into an enucleated oocyte it is possible to “re-set” the genetic
information indicating that the changes in the DNA through development are of
epigenetic origin [31]. Dolly the sheep was the first successful case of somatic cell
nuclear transfer of mammalian cells completing embryonic development; this finding
indicated that the genome of fully differentiated somatic cells retain their
“totipotential” capabilities [32] even after having undergone full differentiation to a
specific cell line. Although Dolly was fairly healthy, other cases of mammalian
cloning exposed abnormal phenotypes and gene expression pattering [33, 34]
implying that epigenetic reprogramming is not thorough after cloning. A
revolutionary contribution was made by Takahashi and Yamanaka in 2006 [3] when
they identified four transcription factors (Oct-3/4, Sox-2, Klf-4, C-Myc) that when
transiently overexpressed in murine fibroblasts are able to drift the phenotype
towards an embryonic character. Those cells were shown to be pluripotent in their
6

ability to differentiate and self-renewing, hence called by the authors pluripotentinduced stem (IPS) cells. A year later the team led by Jaenisch [35] showed that
IPS cells are able to complete embryonic development leading to healthy, normal
animals,

indicating that

IPS

cells

suffer a

complete

nuclear epigenetic

reprogramming ending with similar developmental capabilities to embryonic stem
cells.
The use of IPS cells as a source of autologous cells for therapies offers the
possibility to bypass the complications due to immune rejection and the use of
immunosuppressants. Also, they overcome the ethical issues associated with the
use of stem cells of embryonic origin.
Rodent and human IPS cells have been successfully differentiated into
functional adult cells. Chambers and others were able to differentiate human IPS
cells toward neural progenitors with high efficiency by inhibiting the SMAD signaling
pathway [36]. Also, motor neurons [37, 38], dopaminergic neurons [39], retinal cell
[40], hepatocytes [41], blood cells[42], and adipocytes [43] have been successfully
obtained after in vitro differentiation of human IPS cells. With a similar approach
used for IPS cells generation, it is also possible to transdifferentiate fibroblasts
directly to neuronal progenitors [44] or neurons [45].
In the last four years substantial advances have been made to develop better
methods to produce high-quality IPS cells for their potential use in clinical settings.
The initial reprogramming experiments were done transducing the somatic cells with
genome-integrating viruses; however the disruption of the integrity of the host DNA
is a potential risk for the later development of tumorogenic cells. Different delivery
systems have been designed in order to avoid insertional mutagenesis, which is the
main risk for any kind of DNA-based vector. Later technical advances include the
use of recombinant proteins and mRNA for cell reprogramming.

Table 1

summarizes the reprogramming methods available to date focusing on their
advantage and disadvantages.
The low rate of efficiency of all reprogramming systems is one of the main
obstacles in the generation of human IPS cells. However, this can be improved by
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the use of small molecules like the MEK inhibitor PD0325901, the ALK5 inhibitor
SB431542 [46] and valproic acid, among other molecules.
Method of
delivery
Retroviral vectors

Advantages
High efficiency (0.01-0.5%)

Disadvantages
Insertational

Refs
[3]

mutagenesis
Incomplete silencing
Adenoviral vectors

Low frequency for

Low efficiency (0.001%)

[47]

(7)

integration
Lentiviral vectors +

Higher efficiency (0.1-1%)

Insertational

Cre

Infects non-dividing cells

mutagenesis
loxP sites remain
integrated

PiggyBac

Precise deletion possible

Low efficiency (0.001%)

[48]

Low frequency for

Extreme low efficiency

[49]

transposons
DNA plasmids

integration
Mini-circle DNA

[50]

Low frequency for

Low efficiency (0.005%)

[51]

integration
Proteins

No genetic modification

Low efficiency (0.001%)

[52]

(arginine peptide

Simple protocol

Require many

[53]

tagged)
mRNA

transfection cycles
No genetic modification

Require many

High efficiency (1%)

transfection cycles

[54]

Table1. Delivery methods of reprogramming factors. Values of efficiency
from [55].
I.2.2. Stem cells as a therapeutic tool
Due to the developmental potency of stem cells, they offer a promise for cell
grafting therapies. One of the most explored cell therapies in humans to date is the
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transplant of autologous mesenchymal bone marrow stem cells (BMCs) into the
failing heart.

BMCs have been shown to reduce considerably the mortality of

patients affected with acute infarction and chronic ischemic heart failure [56]. Initially
the mechanism of action was attributed to the regeneration of myocardial tissue by
BMCs, however later evidence indicates that the effects are mainly mediated by the
release of paracrine factors that improve the function of already existing
cardiomyocites or promoting the development of cardiac stem cells (reviewed in
[57]).
BMCs have also been administered to stroke patients. Several clinical trials
are currently in place to determine the efficacy of BMCs when administered
intravenously. Many questions have arisen regarding the mechanism of action of
peripherally administered stem cells; In vitro data suggests that BMCs might
differentiate directly into neurons in the brain; however later data has shown that the
population of implanted cells that reach the target tissue is too low to produce any
type of direct effect. Other lines of evidence suggests that grafted cell release
beneficial factors like anti-inflammatory cytokines and growth factors able to act as
paracrine signals positively influencing the clinical outcome.
Neural stem cells, which can be derived in vitro from ES and IPS cells, have
also been implanted in animal models of neurodegeneration. Yamasaki et al.
reported memory improvement of animals suffering from neuronal loss primarily in
the hippocampal area. They showed that neural stem cells are able to survive,
migrate and differentiate in the host brain [58]. A later report from the same group
indicated that the cognitive rescue due to neural stem cell transplantation is
mediated by brain-derived neurotrophic factor (BDNF) [59] which is released by the
implanted cells. In parallel, neural stem cells have also been implanted in animals
infected with prion diseases. The results indicated that animals receiving neural
stem cells lived longer compared to prion infected animals receiving only the vehicle
[60].
As discussed before stem cell therapy opens new avenues for the
development of new therapeutic alternatives; however until now only a few studies
using IPS cells in models of neurodegenerative diseases are available.
9

I.3.1 Hypothesis
It is possible to generate IPS cells from animals lacking the prion protein and
induce their differentiation into neural precursors.
I.3.2. Objectives
For my dissertation work I have identified three objectives:
1. Development and characterization of IPS cells from prp-/- somatic cells
2. In vitro differentiation of IPS cells into neural precursors and fully
differentiated neuronal cells.
3. Cellular labeling of neural precursor cells for in vivo traceability.

10

II. Materials and Methods
Animals
Wild type 129S2/SvHsd and prp-/- (from here also called KO) transgenic
mice aged 12 months were used for primary culture of fibroblasts. Prp-/- mice were
developed by C. Weissmann [13] in a 129S2 background.. The spring was
genotyped

by

PCR

(5’AGCTGTACAAGAAAAAGCGGC;

3’

CTTGCTCACCATGCAGAGGCC). Stereotaxic injection of cells was conducted
under deep anesthesia by inhalation of 5% isofluorane for induction and 2% during
the surgical procedure. Animals were sacrificed using CO2 inhalation according to
the protocol approved by the Animal Welfare Committee of UTHSC-H.

Primary culture of tail tip fibroblasts
To obtain fibroblast culture from tail tip we followed the protocol described in
[61] with few modifications. Briefly, tail tips from wild type and transgenic mice were
soaked in alcohol and then piled from external skin and chopped in 0.5 cm length
pieces using sterile material. Then, 3 to 5 tail pieces were culture for one day in a
3.5 cm gelatin-coated culture dish containing a thin layer of basic media (DMEM, 1x
antibiotic-antimycotic solution containing Amphotericin B,

Streptomycin, and

Penicillin (Invitrogen), 2 mM L-glutamine and 10% fetal bovine serum). On the
second day more media was carefully added trying to avoid lifting the tail pieces
until a total of 2 ml of media per well. From there, the media was changed every
other day until the emerging fibroblasts reached confluence.
For feeder cells, embryonic mouse fibroblasts (MEFs) were harvested from
mice fetuses following the procedure of Dr. Ana Crane (protocol not published).
Briefly, fetuses were removed from the uterine horns of 13.5 days pregnant female
mouse. Fetuses were washed three times with PBS and then the limbs, head and
visceral tissue was removed and disposed. The remaining tissue was thoroughly
11

minced and then incubated in 0.05% trypsin/EDTA for 30 min at 37oC. After
enzymatic digestion with trypsin most of the cells were found in fine suspension
although some chunks of tissue was also observed. Next, cells were resuspended
in basic media, plated in tissue culture flasks and left in a cell tissue incubator. Cells
were passed three times with trypsin when they reached at least 90% confluence.
To mitotically inactivate the cells, they were trypsinazed and pooled in a 50 ml
conical tube to then be irradiated at 8000 RAD (this step was done by Dr. Crane).
Finally cells were counted and resuspended in cryopreservation media (DMEM plus
10%DMSO and 10% FBS) for long term storage in the vapor phase of liquid
nitrogen.
Culture of Stem cells
ES and IPS cells were culture over a feeder layer of mitotically inactive MEFs
(iMEFs) cells following the protocol provided by Stemgent for mouse IPS cells [62].
Briefly, plates were incubated with 0.2% gelatin overnight at room temperature in
sterile conditions. Next day iMEFs cells were thawed and seeded at 1x105 cells/cm2
in basic media, and then they were incubated overnight at 37oC with 5%CO2 . The
following day basic media was removed, cells were washed twice with PBS and
finally they were incubated in ES media (KO-DMEM media supplemented with 15%
mESC-qualified fetal bovine serum (Atlanta biological), 2x104 units/ml leukemia
inhibitory factor (LIF), 2 mM L-glutamine, 1x non-essential amino acids, and 0.1 mM
β-mercaptoethanol) for at least 2 hours prior plating ES or IPS cells. Everyday ES

media was removed from the plate and fresh pre-warmed media was carefully
added. ES and IPS cells were monitored daily to look for signs of spontaneous
differentiation or excessive density of colonies in the plate. Signs of differentiation
include the presence of merged colonies containing cells of abnormal morphology.
If differentiated cells were spotted, they were mechanically removed by aspiration
with a Pasteur pipette or the complete dish was discarded.
ES and IPS cells were split before colonies appeared to merge. For that the
media was removed and the cells were washed twice with PBS (without
Calcium/Magnesium). Then, 1 ml of prewarmed 0.05% trypsin/EDTA solution was
12

added to 1 well of 6-wells plate and the plate was incubated for 5 min at 37oC. We
added 1 ml of ES media to neutralize the trypsin and then the cells were pipette up
and down to create a single cell suspension. Next, cells were transfer to a 15 ml
conical tube and other 5 ml of media were added to the tube. Finally cells was
centrifuged at 150xg for 5 min, then resuspended in fresh ES media and 1/6 of total
cells were transfer to a new well containing a feeder layer of iMEFs.
For cryopreservation, ES and IPS cells were trypsinazed as described for
passaging

and

then

resuspended

in

cryopreservation

media

(KO-DMEM

supplemented with 10% FBS and 10% DMSO). Then 1 ml of suspension was
transferred to each cryovial. Finally cryovials were stored in a freezing container for
24 hours at -80oC and the next day vials were transferred to a liquid nitrogen tank
for long-term storage.
Control mouse IPS cells were purchase from Stemgent (cat 08-0007),
reprogrammed from fibroblast with a retrovirus encoding the Oct-4, sox-2, Klf-4 and
C-Myc transcription factors produced in Dr. Jaenisch laboratory [63].
Production of iPS cells
Reprogramming of adult fibroblast was carried out by transduction with the four
Yamanaka factors following the same basic protocol [3, 61]. Briefly, fibroblasts were
seeded over gelatin-coated plates at 1x105 cells in one well of 6-wells plate in basic
media and incubated overnight in a tissue culture incubator. Next day, one well of
cells was incubated in transduction media (basic media plus the Oct-4, Sox-2, Klf-4
and C-Myc ecotropic retrovirus. Retroviruses from Stemgent, cat 00-0042) and
another well of fibroblasts was incubated in basic media plus GFP ecotropic virus to
assay efficiency of transduction. Transduction media was supplemented with 4
µg/ml polybrene and plates were centrifuged at 1000xg for 30 min to maximize the
efficiency of transduction. After 24 hours of incubation, transduction media was
removed and discarded and fresh basic media was added to the cells. Viruscontaminated liquid were disposed after inactivation of biohazard material by
incubation for at least 20 minutes in 20% bleach. Solid-contaminated waste was
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collected in closed biohazard bags for their immediate disposal in order to avoid the
formation of dry volatile virus-containing particles. For the same reason, all the
equipment used was cleaned with 10% bleach. Next day cells were passaged and
plated at 1x104 cells per cm2 in a gelatin-coated plate in basic media. After 24 hours
the media was changed to ES media and then fresh media was added every other
day. Cells were monitored daily for the appearance of colony with similar
morphology to ES cells.
Characterization of IPS cells
Pluripotent cells were characterized by staining with Alkaline Phosphatase
detection kit (Millipore) following the recommendations of the manufacturer. Briefly,
cells were incubated for 15 minutes in a solution containing two parts of Fast Red
Violet solution (0.8g/L stock) and one part of Napthol AS-BI phosphate solution
(4mg/mL) in AMPD buffer (2mol/L), pH 9.5. Then, cells were washed three times
with PBS and finally cells were analyzed under a bright field inverted microscope
(Motic AE30).
For the embryoid bodies formation assay, IPS cells were cultured for 3
passages over gelatin-coated plates to get rid of the feeder cells. Then the
pluripotent cells were grown in the presence of basic media in microwells following
the

guidelines

provided

by

the

manufacturer

(Aggrewell

400,

Stemcell

Technologies). Briefly, plates containing microwells were filled with DMEM/F12
media and centrifuged at 2000xg for 5 minutes in order to remove bubbles. After the
DMEM media was removed, a suspension of 1,2 x 105 cells was added to each
well and the plate was centrifuged to 100xg for 3 min to pull own the cells to the
bottom of the microwells. After 24 hours of incubation at 37oC, 5% CO2 the media
was gently replaced for fresh one. After 48 hours past the initial incubation cells
were lifted off from the bottom of the well by slowly pipetting up and down. The
aggregates of cells were passed through a 35 µm cell strainer in order to retain the
aggregates while wash out single cells. Aggregates were washed three times with
PBS and then collected in a conical tube by inverting the strainer. Finally the cell
aggregates were plated in ultra-low adherence wells in basic media and incubated
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for another 2 weeks. Media was changed every other day by removing half of the
volume with a Pasteur pipette and adding the same volume with fresh pre warmed
media.
For the teratoma formation assay wt and mutant feeder-free IPS cells were harvest
by trypsinization. The reaction was stopped by dilution in PBS and cells were counted.
Next, cells were centrifugated at 100xg for 5 minutes at room temperature and the
concentration

was

adjusted

to

1x105

cells/µl

in

DMEM

supplemented

with

antibiotic/antimycotic solution. Cells were kept in ice until use. Animals were anesthetized
with by inhalation of 5%-2% isofluorane. After the animals were unresponsive to

physical pain it was placed in a sterotaxic apparatus with constant supply of 2%
isofluorane. Then, the upper are of the head of the animal was shaved and a small
incision was made (0.5-0.8 cm). Then, a small orifice was drilled in the cranium at 2
mm posterior of bregma and 2 mm right of the middle line. Next, using a Hamilton
syringe 2 µl of cells was injected in the hippocampal area of the right hemisphere.
Finally the incision was stitched with silicon coated braided silk (Softsilk) and the
animal was placed over a warm pad until recover from anesthesia. Animal were
sacrificed after 3 weeks and brain tissue was fixed for histological analysis.
Differentiation of iPS into neural precursor cells
For differentiation to neuronal precursors cells, feeder-free IPS cells were
culture over gelatin-coated plates in ES media for at least 3 passages. Then, cells
were treated under different protocols:
Protocol 1 [64]: Cells were resuspended in cellular aggregates media
containing DMEM, 10%FBS, 2mM L-glutamine, 1x non-essential amino acids, and
0.1 mM beta-mercaptoethanol in a low-attachment plate. Media was changed after
2 days. At the 4th and 6th day the media was changed and supplemented with 5µM
retinoic acid (RA. Sigma). At the 8th day the spheres were disrupted by enzymatic
digestion with 0.05% trypsin/EDTA and reseeded in a poly-ornithin/laminin coated
dish in N2 media (DMEM/F-12 plus 25 ug/ml insulin (sigma), 50ug/ml human apotransferrin (Sigma), 20 nM progesterone (Sigma), 100 nM putrescine (sigma), 30
nM sodium selenite (Sigma), 50 ug/ml BSA (Sigma), pH 7.0-7.8).
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Protocol 2 [65]: Cells were resuspended in DMEM/F12 –Neurobasal (Gibco)
(1:1) medium supplemented with (25 µg/ml insulin, 100 µg/ml apo-transferrin, 6
ng/ml progesterone, 16 µg/ml putrescine, 30 nM sodium selenite) plus 50 µg/ml
bovine serum albumin fraction V, and B27 supplement (invitrogen) and replated in a
gelatin-coated plate. Media was changed every day for at least 6 days.
Protocol 3 [66]: Cells were resuspended in Neural precursor (NP) media
containing DMEM-F12 media (Invitrogen) and Neurobasal (Gibco) (1:1) medium
supplemented with 1x N2 (Invitrogen), 1x B27 (Invitrogen), 15 ng/ml basic fibroblast
growth factor (bFGF, stemgent),

50 ng/ml epidermal growth factor (EGF,

stemgent), 50ug/ml apotransferrin (Sigma) in a gelatin-coated dish. Media was
changed every day for 6 days and then cells were passaged by digestion with
0.05% trypsin/ETDA for 1 min at 37oC. To neutralize the enzymatic reaction, cells
were diluted 5x in PBS containing calcium and magnesium, centrifugated for 5 min
at 100xg and then resuspended in NP media to finally re-seed in a gelatin-coated
dish.
Protocol 4: Cells were resuspended in NP media supplemented with 5uM RA
and plated in a gelatin-coated dish. The second day media was replaced with the
same formula. At day 3rd and 4th media was changed and replaced with NP media
supplemented with 3 uM RA. At day 5th and 6th madia was changed and replaced
with NP media supplemented with 1 uM RA. Between every media change cells
were washed with PBS to eliminate non-attached cells. At day 7 cells were
detached by incubation with 0.05% trypsin/ETDA for 1 min at 37oC. To neutralize
the enzymatic reaction, cells were diluted 5x in PBS containing calcium and
magnesium, centrifugated for 5 min at 100xg and then resuspended in NP media
supplemented with 1uM RA to finally re-seed the cells in a gelatin-coated dish for
expansion.
Neural precursor cells were storaged in cryopreservation media containing
DMEM/F12 media supplemented with N2, B27 and 10% DMSO. Vials were slowy
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frozen at -80oC in freezing container and then stored in the vapor phase of liquid
nitrogen.
Differentiation of neural precursors into neurons
For neuronal differentiation NP cells were cultured over L-ornitin/laminin
plates in the presence of NP media lacking bFGF and EGF changing the media
every two days. For glial differentiation cells were cultured over gelatin-coated
plates in the presence of NP media lacking growth factors but supplemented with
1% fetal bovine serum [66].
Labeling of neural precursor cells
Neural precursor cells were seeded at 1x105 cells/cm2 in a gelatin-coated
plated. Next day cells were transduced by adding EGFP-retrovirus produced in the
lab. For that packaging 293T derived cells transfected with pol and gag genes
(Platinium-E cells, CellBiolabs) were cultured in basic media in the presence of 10
µg/ml blasticidine and 1 µg/ml puromycine for selection. Cells were passaged by
trypsinization when they reached 70% confluence. One day before transfection cells
were seeded at 6x104 cells/cm2 in absence of antibiotics. Next day we transfected
the Platinium-E cells with 2 µg of pMXs-IRES-GFP vector (for a 3.5 cm well) using a
lipophilic carrier (X-treme, Roche). After 48 hours the supernatant was collected and
passed through a 45 µm pore filter. Then it was centrifuged at 26000 rpm for 2
hours at 4oC in a 70-Ti rotor (Beckman). After centrifugation the supernatant was
eliminated and NP media was added to the pellet that contained the retroviral
particles. The solid pellet soaked in media was left overnight at 4oC after which the
pellet was disaggregated. The virus-containing media was added to the neural
precursors at several concentrations and polybrene was added to some wells at 4
µg/ml final concentration. Also, some wells were centrifuged at 1000xg for 30 min
after the addition of the viruses. Next day the media was changed for fresh virusfree NP media and from there the culture was treated as normal neural precursor
cells.
Immunochemistry
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Cells were fixed in the plates with 4% paraformaldehyde and then post-fixed
with ice cold 100% methanol for 20 min at -20oC. Then, cells were blocked for 1
hour at room temperature with Tris buffer solution (TBS) supplemented with 0.25%
triton X-100, 3% BSA and 3% normal donkey serum. After 2 washes with TBS, cells
were incubated overnight at 4oC in the presence of primary antibody diluted in TBS
plus 0.12% triton X-100 and 3%BSA. Antibodies used in this study includes: SSEA1 coupled to PE (Stemgent), Oct-3/4 (Stemcells Technologies), Musashi (Cell
Signalling), PAX-6 (DHSB), SOX-2 (R&D), Vimentin (DHSB), and TujI (Chemicon).
Next day cells were washed again with TBS and secondary antibody was added at
a 1:400 concentration for 1.5 hours at room temperature using the same diluting
solution as done for incubation with primary antibody. Next, cells were washed 3
times with PBS, then incubated for 5 min in DAPI solution for nuclear staining and
washed again. Finally, a drop of mounting media was added and then covered with
a round coverslip before image acquisition. All pictures of fluorescent samples were
taken using a BFC360 FX camera coupled to a DMI6000B Leica microscope.
Phase contrast pictures were taken using a Moticam 2300 camera counted over a
Motic AE30 microscope.

Electrophoresis and Western blotting
Protein electrophoresis was performed in a 12% bis-tris acrylamide gels. Gel
were western blotted against a nitrocellulose membrane for 1 hour at 400 mAmp.
Then, the membrane was blocked with 5% milk in washing buffer (PBS plus 0.05%
tween-20) for 1 hour at room temperature. Then the membrane was incubated
overnight at 4oC with antibody 6D11 (Covance) diluted 1:5000 in washing buffer.
Next day the membrane was washed three times 10 minutes each with washing
buffer to then be incubated in a dilution of sheep anti-mouse IgG coupled to
horseradish peroxidase (GE). After other 3 washes, we added an appropriated
substrate for horseradish peroxidase (ECL Plus Western Blotting Detection System,
GE) and the chemiluminescent signal was captured in a Chemidoc dark chamber
(Bio-Rad).
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Cell sorting
For sorting of IPS cells they were detached from the plates by digestion with 0.05%
trypsin/EDTA, centrifugated at 150xg for 5 min and resuspended in cold sorting
solution containing Hank’s salt buffer solution (HSBS) without calcium or
magnesium supplemented with 10 mM HEPES buffer, 2% heat-inactivated ESCqualified FBS , 2 mM glutamine, non-essential amino acids, 2x104 units/ml LIF and
0.1

mM

β–mercaptoethanol,

1x

antibiotic-antimycotic

solution

containing

Amphotericin B, Streptomycin, and Penicillin (Invitrogen). Next, cells were taken
to the Cytometry and Cell Sorting Facility at Baylor College of Medicine for cell
sorting. IPS cells were sorted using a FACSAria II sorter

(BD Biosciences)

equipped with a yellow-green (561 nm) laser for PE excitation. Neural precursors
were sorted using a FACSAria equipped with a blue (488 nm) laser. After sorting
cells were collected in the appropriated cold media (ES or NP media) and then
culture under standard conditions.

III. Results
III.1. Prp-/- mice do not express the prion protein
The animals were genotyped to confirm the lack of the ORF for prnp gene in
their genome.

We performed a conventional PCR using the primers listed in

material and methods section. As expected we observed one band in wild type
mice but not in KO mice (figure 1C), confirming that the gene coding for prion
protein is not in the genome of the transgenic mice. Prion protein is mostly
expressed in brain cells so we wanted to check the expression of PrP in the brain of
KO prp mice in comparison to wt mice. We homogenized the brain of wild type and
Prnp Ko animals in PBS plus a cocktail of proteases inhibitors at 10% (w/v). Then
the samples were submitted to electrophoresis in a 12% denaturant Bis-Tris
acrylamyde gel followed by western blotting. We observed the three typical bands
for PrP using the 6D11 antibody in wild type mice and the lack of it in KO animals
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(figure 1A). In parallel we ran another electrophoresis and the gel was stained with
coomasie blue to confirm that we loaded the same amount of proteins (figure 1B).
III.2. Generation of primary culture of fibroblasts from prp-/- and wild type
mice
As described in the material and methods section, fibroblasts were cultured
from the tails from 1 year old wild type and prp-/- mice. Only tail pieces attached to
the bottom of the well were able to give rise to new cultured cells; the rate of
attachment was similar in both set of samples. The most critical factor to obtain a
high rate of attachment of growing cells was the experimental manipulation when
adding media more than the cell type. Figure 2 illustrates the development of
fibroblasts from KO tails
III.3. Cellular reprogramming of terminally differentiated fibroblasts into
induced pluripotent stem cells.
To reprogram the fibroblast from prp-/- mice we used the protocol described
by Yamanaka consisting on the overexpression of four transcription factors [61]. For
that, we transduced the fibroblast at passage 3 with 4 ecotropic retroviruses coding
for Oct-4, Soc-2, Klf-4 and C-Myc. As a control of transduction we infected another
set of cells with the same vector encoding only for GFP (Figure 3A). We observed a
transduction efficiency of 25% as evaluated by microscopy after 48 hours post
transduction. A second measurement of the quantity of transduced cells was made
by staining a subpopulation of transduced fibroblasts with antibodies against the
ectopic genes Sox-2 and Oct-4 (figure 3B-E). We observed that 22% of cells were
positive for Sox-2 and 27% were positive for Oct-4. Taking together our results
indicate that around 25% of cells express at least one of the ectopic reprogramming
factors.
Two days after transduction, cells were passaged and reseeded in gelatincoated wells. When they reached 70% confluence media was changed to ES media
which contain LIF, a inhibitory cytokine of cell differentiation of mouse pluripotent
cells [67]. Soon after (two days) media switch we observed the emergence of
20

clusters of cells with abnormally high cytoplasm/nucleus ratio (fig 4A); these types
of formations are described by other groups as primordial reprogrammed cells,
which include semi and fully undifferentiated cells. Some of these clusters were
transients, dying after 2-3
3 days. After 10 days of adding the reprogramming media
we were able to observe colonies morphologically reminiscent of mES cells.
cells The
colonies have bright and smooth edges, with no observable separation between
cells (Figure 4B).. We also observed the formation of amorphous non-reprogrammed
colonies and rapidly growing KO fibroblasts (Figure 4B)
4B). We did not observe cells of
abnormal morphology or abnormal growth rate in the cells treated with the GFPGFP
retroviral vector
or (fig 4C).

Figure 1. PrP is expressed in wild type mice but not in prp -/- mice. (A)
Crude homogenate of KO prp and wt mice brain were western blotted against the
prion protein (6D11 antibody 1:5000 dilution).
We observed the three
glycoforms of the prion protein in wild type but not in KO brains. (B) Same
samples were stained with coomasie to confirm equal amount of total protein. (C)
DNA extracted from tails of KO and wild type mice were submitted to PCR to
amplify a segment of the prp gene
gene.. We observed an amplification of DNA in wild
type mice but not in KO mice. Each line represents different animals. Last line
corresponds to negative control (PCR reaction mix without DNA).
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Figure 2. Primary culture of prp
prp-/- fibroblasts. Phase contrast photos of the
development of primary fibroblasts from adult prp-/- tail tips.. Fragments of tail
were seeded in gelatin
gelatin-coated wells. After two days we
e observed small rounded
immature cells growing off the piece of tail (marked with a yellow start star in
Panel A, 100x magnification). Panel B shows a detail of the nascent cells from A
(200x magnification). After 5-6 days the rounded cells started to elongate like
the cells shown inside the yellow ovals, panel C. After 8
8-9
9 days cells reached
confluence
luence (panel D, 100x magnification) and were passaged using 0.05%
trypsin/EDTA. We
e did not observed any difference between KO and wild type
cultures.
In order to isolate mES
mES-like
like colonies we manually detached the cells from the
plate using a rounded tip glass Pasteur pipette. Then they were collected and
manually disaggregated to obtain a single cell suspension.

Finally cells were

reseeded over a layer of irradiated MEFs preconditioned with reprogramming
media. After two manual passages of mES
mES-like
like colonies on feeder cells we
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performed the alkaline phosphatase (AP) assay for pluripotency. AP is an enzyme
expressed in embryonic stem cells and other cell types, being an unspecific but well
accepted marker for screening of pluripotency [68]. To carry out the test cells were
incubated for 15 min in the dark in the presence of a diffusible substrate for alkaline
phosphatase turning the cells a violet color after the reaction takes place. We
observed that only 34 ± 9.2 % (SE) (n=7 colonies, 376 cells) of the cells belonging
to a same colony were positive for AP (fig 5A-C). We performed a second test for
pluripotency, in this case we stained the live cells with an antibody for the surface
protein SSEA-1[69]. In agreement with the previous test we observed that only a
subset of cells was positive for SSEA-1 (Fig5 D-F). We estimated that the
percentage of positive cells is 34.2 ± 12.6% (SE) (n=7 colonies, 363 cells). The
same population of cells was submitted to flow cytometry to detect the signal
emitted by SSEA-1 (coupled to DylightTM PE). The results indicate that 37.4% of
single cells were positive for SSEA-1. These data taken together, suggested that
our procedure resulted in the formation of mES-like cells but that colonies contained
a mixture of pluripotent and differentiated cells.
To isolate a pure population of pluripotent cells we submitted the cells to flow
cytometry coupled to cell sorting. Prior to flow cytometry cells were detached by
trypsinization and kept in cold sorting solution (HSBS buffer without calcium or
magnesium supplemented with HEPES, 2%FBS and glucose) until analysis. The
results indicated that 25% of total event were positive for the SSEA-1 marker
(37.4% of singlets) (Figure 6). Those positive cells were sorted and captured in
mES media to then be seeded over a fresh layer of feeder cells conditioned in mES
media.
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Figure 3. Efficiency of viral transduction. Cells were transduced with a GFP-coding
GFP
retrovirus and immunostained for the ectopic expression of Sox
Sox-2
2 and Oct-4.
Oct
After
48 hours post transduction the amount of GFP positive fibroblasts was close to 25 %
(A). After replate the fibroblasts we evaluated the number of cells overexpressing
Sox-2 (B-C) and Oct-4
4 (D
(D-E).
E). In both cases we observed a similar percentage of cells
expressing those markers, 22% and 27% respectively. Bar: 100 nm.
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Figure 4. Generation
neration of prp
prp-/- IPS colonies..
Fibroblasts were transduced
transduc
with
retrovirus for the Oct-4,Soxx-2, Klf-4 and C-myc
myc genes. After a few days we observed the
emergence of primitive colonies (A). At 10 days post transduction we were able to
identify colonies with similar morphology to mES cells ((yellow
yellow arrow) between
amorphous semi-differentiated
differentiated colonies (red arrow) and overgrowing KO fibroblasts
(orange arrow) (B). The fibroblasts transduced only with GFP
GFP-vector
vector did not show any of
the characteristics observed
ved in the reprogrammed cells after 10 days(C).
days
Magnification:
100x

Figure 5. Primary mES-like
like colonies contain pluripotent and non-pluripotent
non
cells. Rudimentary colonies of IPS cells were partially positive for pluripotency
marker alkaline phosphatase (violet cells in panels A-C).. Note that not all cells were
positively labeled within the same colony (A
(A-C). The same phenomenon was
observed when cells were stained for the expression of SSEA-1
SSEA
by
immunofluorescence (D-F). Magnification 100x.
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III.4. Characterization of putative Induced Pluripotent Stem Cells
After one day in culture, sorted cells formed colonies similar in shape
(Figure7A). In addition, cells forming the new colonies were all positive for the AP
assay (fig 7B), in contrast to cells observed prior to sorting. To further establish if
the new colonies were induced pluripotent stem cells we ran a series of
immunostaining assays using specific markers for pluripotency like Oct-4, Sox-2
and SSEA-1. The studies were done in parallel using our iPS cells generated from
Prnp KO mice and commercially available mouse iPS which have been extensively
characterized for pluripotency [35]. Our results show that virtually all

the cells

forming the clusters were positive for those markers but not the cells surrounding
the colonies, which are irradiated MEFs, used as a feeder layer. These data, taken
together, strongly suggest that the sorted cells were IPS cells. To confirm this
hypothesis we performed two other assays for pluripotency: embryoid body
formation and teratoma formation assay.
Embryoid bodies (EB) are sac-like structures developed in vitro from
embryonic stem cells containing cells belonging to ectodermal, mesodermal and
endodermal lineages [70]. We submitted the putative IPS cells (sorted and cultured
population of cells) to two types of EB assay: in low-adhesion plates and in
microwells as described in material and methods. For both assays we passaged
both the putative IPS cells colonies as well as control IPS cells three times in
gelatin-coated plates to eliminate iMEFs. Cells were then cultured in suspension in
a low-attachment plate in basic media and incubated under standard conditions for
2 days without disturbances. In the alternative protocol, the same density of cells
was seeded over a grid of microwells coupled to a cell culture plate (Aggrewell,
Stemcell technologies).

After 2 days in culture, cells in low-attachment plates

showed adherence between them and grew in clusters (not shown).

Cells in

microwells grew at as clusters at the bottom of the wells (fig 8A, 8C). They were
detached from the bottom of the wells by carefully blowing media and then
transferred to a low-attachment plate were they kept growing as spherical
structures. After 10 days in culture, both systems gave rise to EB, with the main
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difference between them
m being that the microwells gave rise to more uniform
structures in size and shape. Starting at 11 days in culture we observed the
presence of contractile cells near the pole of the EBs
EBs.. This suggests that KO iPS
cells are able to differentiate into cells of mesoderm origin
origin,, supporting the
pluripotency capability of the newly generated IPS cells from KO fibroblasts..
fibroblasts. Other
authors also have observed the appe
appearance of contractile
ontractile cells in EBs. They
identified those cells as cardiomyocites [70-72]. No differences in morphology
(figure 8 A-D) were observed between our KO iPS and commercially
commercia obtained wt
IPS cells.

Figure 6. Selection of IPS cells
cells. Primary mESC-like
like cells were stained with
SSEA-1
1 antibody and then submitted to flow cytometry in a FACSDiva
instrument. The Y–axis
axis of the dot plot diagram represents the absorbance for
green fluorophores while the X
X-axis
axis represents the absorbance emitted
emitt by the
dylight549-SSEA-1
1 antibody. The left panel shows the result of the negative
control (non stained) cells while the right panel depicts the emission spectrum
for the stained cells. The more SSEA
SSEA-1-positive
positive cells (Dylight+, purple
population) were sorted
orted and captured to then be cultured as IPS cells.

Figure 7 (next page). Characterization of prp KO IPS cells
cells.. Sorted SSEA-1
SSEA positive
cells formed colonies reminiscent to mES cells when cultured over feeder cells (A).
Those colonies were positi
positive for alkaline phosphatase test (B),
(B) a marker for
pluripotency. Similar expression of Oct
Oct-3/4 (C-H), SSEA-1 (I-N)
N) and Sox-2
Sox (O-T) was
observed by immunocytochemistry for both commercially obtained wild type bona-fide
bona
IPS and our KO IPS cells. Scale bar: 2
200 µm.
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A second assay to verify the pluripotency capability of the newly generated
IPS was a teratoma formation assay. For that we intracranially injected 2x 105 cells
in mice in the hippocampal area of the right hemisphere. One animal died after
three weeks of a severe brain tumor. Surviving animals were sacrificed after 4
weeks post injection and brain tissue was analyzed. All the animals (5/5) showed
tumors, suggesting that the KO IPS cells are able to differentiate and form solid
tumors. Figure 8E-H shows the histopatological profile of the tumors generated in
wt animals. Figure 8 G-H shows details of the structures found in the brain of KO
iPS-injected animals as vascular tissue and cartilage. The proportion of animals
developing tumors and the morphological characteristic of the tumors were very
similar when the experiments were done with both our KO IPS and the well
characterized wt IPS cells.

Figure 8 (next page). Pluripotency assays. Embryoid body formation assay in was
induced by incubating the cells in microwells. Panel A shows the microwells seeded
with KO-IPS after 48 hours of plating while panel C shows the WT-IPS at the same
point time (200x magnification). Then, spheres were transfer to a low-attachment
plate where they grew in suspension. After 7 days cells formed bigger spheres as
shown in panel B for KO-IPS and panel D for WT-IPS (100x magnification). For the
teratoma formation assay KO-IPS and WT-IPS cells were injected into the brain of
wild type animals. At 3 weeks post implantation animals were sacrificed and their
brain fixed for H&E staining. Both sets of cells formed solid tumors. Panel E shows
a mosaic of pictures taken a 5x magnification of a brain injected with KO-IPS while
panel F shows a brain injected with WT-IPS. Panel E and H show a detail of
structures found in KO-IPS injected brain. We observed that the lesion present
hypervascularization (G) and the development of other structures with morphology
similar to cartilage (H). Scale bar: 100 µm.

29

30

III.5. Differentiation of IPS cells into neural precursors
The next step after obtaining IPS cells from KO fibroblast was to differentiate them
into neural precursors. We tried three published protocols of differentiation to
evaluate which one resulted in the most homogeneous long lasting population of
NPs. The first protocol applied was the one published in 2007 by Bibel et al [64].
Briefly, IPS cells are culture as adhesion free-cells in DMEM supplemented with
FBS, glutamine, non-essential amino acids and RA. After a few days we observed
that cells formed cellular aggregates (CA) in suspension (Figure 9A) that when were
cultured over gelatin-coated plates formed heterogeneous populations of cells
judged by their morphology (not shown). Since we were looking for homogeneous
populations we discarded this protocol. The second approach was based on the
article published by Smith et al. in 2005 [65]. In contrast to the previous approach,
the cells were grown as adherent monolayer over gelatin-coated dishes in a serumfree medium constituted by a mix of DMEM/F-12 and neurobasal media
complemented with B27 and a cocktail of apotransferrin, putrescine, insulin, selenite
and progesterone. After a few days in culture cells detached from the bottom of the
plate giving an extremely low yield of putative neural precursor cells (Figure 9B).
We estimated a reduction in the number of cells of 95%. The third protocol applied
was that published by Pollard et al in 2006 [66]. As in the previous protocol cells
were cultured over a gelatin-coated surface in the presence of NP media
(DMEM/F12/Basal media plus B27 and N2 supplements and human apotransferrin,
Fibroblast Growth Factor (FGF), and Epidermal Growth Factor (EGF)).

Cells

showed better adherence to the bottom of the plate only when cultured at high
concentrations (Figure 9C); at lower cell density cells died and detached. We tried
to optimize this procedure by adding RA (which is known to induce differentiation
toward neuronal lineage and improve cell survival [73]) and leaving the cells to
reach over confluence prior to switch the media from mES to NP media. Upon
changing the media, we observed a massive detachment of dead cells that were
removed by washing the plate twice with PBS containing calcium and magnesium
after each daily media change. However, we also observed constant proliferation of
new adherent cells (Figure 9D); Then, we implemented another protocol (personal
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finding, not published) which combine the use of growth factors and RA. We plated
the pluripotent cells in at 3x105 cells/cm2 in NP supplemented with 5 µm RA. Next
day media was changed for the same fresh solution. At day 3 and 4 media was
removed and replaced with NP supplemented with 3 µm RA, and finally on day 5
and 6 media was removed and replaced with NP media supplemented with 3 µm
RA. We also observed a high rate of apoptotic detaching cells and proliferation of
the adherent layer. The final population was passaged by trypsinization (0.05%
trypsin/EDTA) at day 6 or 7 over a gelatin-coated plate and then the media was
changed every other day (NP media supplemented with 1 µm RA).

After 2

passages cells showed a triangular morphology in the soma and with short
projections interlocking the cells. Cells with similar morphology are found after the
differentiation process of mouse ES cells as describes in [66]. The authors
described those cells as similar to radial glia cells capable of generating neurons,
astrocytes, and oligodendrocytes.
We observed the same outcome, both in terms of morphology and yield,
when started with KO IPS or wt IPS cells (fig 9E-H), suggesting that KO IPS cells
behave like wt cells in terms of neuronal progenitor development. It is important to
mention that KO-NP cells were intracranially injected in wild type animals and we
did not observe any evidence of brain tumors at least 6 weeks after implantation.
This indicates that the differentiated population of cells losses the tumorigenic
potential.
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Figure 9. Development of neural pr
precursor cells from IPS cells.
cells WT IPS cells
cultured as described Bibel et al.. formed structures similar to EBs (A) that when
cultured in adhesive plates developed in heterogeneous populations (not shown).
shown)
When IPS cells were cultur
cultured in a serum-free media lacking growth factors we
observed massive cell death (B), which was reversed by the administration of bFGF
and EGF (C). The number of live cells was improved by applying retinoic acid to the
media (D). Cells were passaged by treat
treatment
ment with trypsin while maintaining a radialradial
glial cells morphology (E
(E-F).
F). KO IPS cells showed the same evolution as wt cells (G(G
H). A-E,G: 100X
0X magnification; H,F: 20
200X magnification.
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III.6.
6. Characterization of Neural Precursors cells.
To further characterize that the population of cells generated by incubation in
media containing EGF, FGF and RA consist of NP cells, we tested if the cells
express markers for neura
ral precursor cells.

Fig 10. KO-NP
NP cells expressed neu
neural precursor markers.. KO fibroblasts
(panel A) and KO-NP
NP (panel B) cultures were fixed for immunocytochemistry. KOKO
NP cells showed an upregulation of nestin, musashi and Pax6. We observed
equivalents results for wild type cells. Vimentin, another marker for neural stem
cells, was expressed in NP cells but not in IPS cells (C, KO
KO-NP
NP cells, D, Wt-NP
Wt
cells). Scale Bar: 200 µm
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We compared the expression of those markers against the basal expression
in fibroblasts and we observed the up regulation of Nestin, Musashi and Pax6 (fig
10 A-B). Also, we observed an upregulation of the marker for neuronal stem cells
Vimentin in both KO NP and wt NP cells relative to the IPS cells (not shown).
To further characterize the developmental properties of NP cells we induced
their differentiation into neurons and glial cells. For neuronal differentiation we
seeded the cells over an ornithine/laminin treated dish in the same basic formula for
NP differentiation, but lacking the growth factors. Although most of the cells died,
after 10 days we observed rounded cells and long projections resembling pyramidal
neurons (fig 11A). Also, we found that those cells were positive for the neuron
specific TuJI antibody (fig 11C). For glial differentiation NP cells were seeded over
a gelatin treated plate in the presence of NP media lacking growth factors but
supplemented with 2% FBS. Under this condition cells survived and grew into flat
and expanded cells. Some of those showed a protuberant nucleus at the center of
the cell (fig 11B). Although the morphology resembles glial cells we need to perform
further analysis to confirm the glial-like properties of the resulting population. Taken
together this data suggest that the initial KO NP population of cells generated from
skin-derived IPS cells have the intrinsic capability to differentiate into neurons.
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Fig 11. KO neurons differentiated from KO neural progenitors cells.
cells
After 10 days in culture in NP media neurall progenitor cells showed a
morphologically neuronal phenotype (A). Also, they expressed markers for
neurons like TujI (C). NP cells cultured in glial media showed a glial
phenotype (B) not expressing the neuronal marker TuJl (D).
(D) Bar: 200 µm

III.7. Generation of traceable NP cells
In order to track
ack the NP cells once implanted into the brain of experimental
animals we explored three different approaches: cell labeling with fluorescent
lipophilic tracers, transfection with GFP coding vectors and infection with GFPGFP
coding retrovirus.
roach was implemented by treating the NP cells with SPSP
The first approach
DiOC18(3), a fluorolipophilic dye which is able to diffuse laterally within cellular
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membranes.

After incubation of the cells with SP-DiOC18(3) for 4 min at 37oC

followed for 15 min at 4oC we observed that the lipophilic dye effectively marked the
cells as seen by microscopy (fig 12A-B). Those cells were reseeded in a gelatincoated plate containing glial media to evaluate the survival after staining. Even after
12 days of culture we observed that cells survived and retained the marker along
the plasma membrane and internal compartments (fig 12C-D).
The second approach was to transfect the cells with a GFP-coding plasmid
using lipofectamine. The initial result indicated a transfection rate of 50%; however
the transfected cells died soon after two passages (data not shown). A second
attempt to make the cells express GFP was to transduce them with a GFP coding
retrovirus. For that we transduced platinum E cells (NIH-3T3 derived cells) with the
pMXs-IRES-GFP vector to induce the production of GFP-coding retrovirus. We then
concentrated the viruses by centrifugation to finally resuspend them in NP media.
We tested the efficiency of transduction in wild type NH3 fibroblasts obtaining
efficiency close to 100% when evaluated by microscopy (data not shown). Using the
same batch of viruses we infected KO-NP cultures. After 24 hours we replaced the
virus-containing media with fresh NP media and evaluated the presence of green
NP cells. We observed expression of GFP in some cells after 48 hours postinfection (fig 12E-F). We expanded the culture, however after two passages the
fraction of positive cells was lower than expected. To enrich the GFP (+) population
we submitted the cells to flow cytometry followed by cell sorting by using the
FACSDiva system (fig 12 I). A pure population of GFP-positive cells was collected
and then cultured under standard conditions for NP cells. We observed that after
few days GFP (+) cells present in the culture counted for only a small percentage of
the total population. This result suggested that the expression of GFP is silenced in
NP cells or that the accumulation of GFP might be cytotoxic.
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Fig 12. Traceability of NP cells. In order to be able to trace NP cells after
grafting we stained the cells with SP
SP-DiOC18(3), a lipophilic fluorescent dye (A(A
B). After staining those cells were cultured for at least to 9 days (C-D)
(C
showing
that are cells are viable. We also transduced the cells with GFP-coding
GFP
retroviruses observing
ng positive cells after 48 hours post
post-transduction
transduction (E-F).
(E
After two passages NP cells (G
(G-H)
H) were submitted to cell sorting and GFPGFP
positive cells were collected for further expansion. The initial population was
homogeneously fluorescent, however we obser
observed
ved a progressive dilution of
GFP-positive cells (J-K,
K, after 5 days in culture).

III.8. Future Plans
In order to test the working hypothesis
is we need to implant the neural
neur
precursors derived from KO PS cells, as well as their wild type counterpart, into
animals infected with prions to the evaluate if they perform better in a series of tests
to evaluate the clinical symptoms, survival rate
rate,, neuropathological analysis of the
th
brain and biochemical parameters. To set up the conditions for testing the effect of
NP implantation in animals infected with prions, we performed a detailed
characterization of this animal model. Prions were injected i.p. in wild type mice.
mice
The most important
ortant parameter to analyze is the survival time of the treated animals
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(Fig. 13A). We expect to see an increased survival of the animals receiving the
treatment, which should be dependent on the amount of cells implanted.
Furthermore, we will evaluate the performance of the animals in the rotarod test,
which measures motor coordination. Also, animals will be tested in an open field
assay to measure general physical activity and response to a new environment. For
neuropathological analysis, half of the brain will be fixed in paraformaldehyde for
H&E staining in order to measure the intensity of brain lesions product of the
disease (vacuolation), as well as the pattern where those sings appear (Fig. 13B).
Astrogliosis will be evaluated by immunostaining with an anti-GFAP antibody and
the accumulation of the prion protein with an anti-prion antibody (fig 13C and D).
Figure 13 shows those results for an untreated animal.
In future experiments we would like to increase the efficacy of the stem cell
treatment

by

using

engineered

cells

aimed

to

release

BDNF

to

the

microenvironment. Currently, we are creating stable lines of NP cells transfected
with BNDF. In parallel we are working to create stable lines of NP capable of
releasing beta-sheet breaker peptides (BSBs), which have been shown to inhibit
and reverse prion replication in vitro and in vivo [28] We designed a gene called
“Beta-sheet breaker Super Gene” which include an exportation signal followed by
BSB peptides linked by thrombin-cleavage segments (PCS-T). The BSB sequences
are based in data from previous publications where the authors showed the effects
of peptides on the blockage of fibrillation of beta-amyloid and prion peptides [28,
30]. We expect that the cells will translate the peptide and then it could be
transported to the extracellular space. Once outside the cells the arg-peptidase
thrombin can cut the peptide to release several fragments of BSB. Diagram 14
depicts the design of the gene. We chose the PCS-T linker since thrombin is known
to be secreted by brain endothelial cells [74] and thrombin is an activator of
astrogliosis [75, 76], which strongly suggest that thrombin is present in the brain
parenchyma of prion infected animals. Moreover, the cell implantation surgery will
open wounds disrupting the brain-blood barrier, allowing the uptake of thrombin in
the brain.
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Before implantation we should determine if: 1) the complete BSB peptide will
be externalized by the NP cells, 2) if the thrombin is able to catalyze the cleavage of
the peptide, and 3) if the peptides are effective in vitro. To analyze tthe
he expression of
BSBs we produced an antibody specific against prion and beta
beta-amyloid
amyloid which can
be used in ELISA assays. If this approach fails, we will clone the BSB gene in
tandem with a DKK tag to then detect the tag with an anti
anti-DKK
DKK antibody. Once we
are
re sure we have expression of BSBs, the peptide will be digested by thrombin in
vitro and then the molecular weight of the resultant peptides will be analyzed
analyze by
western blot. 4) Finally, we will test if the BSB peptides are as effective when they
are flanked
ked by the residuals amino acids of the PCS-T
T linker as when they are not.

Fig 13. Neurodegeneration associated to prion diseases
diseases.. Mice show clear
signs of neurological deficits as weakness and loss of motor coordination after
175-185
185 days after intrape
intraperitoneal
ritoneal inoculation of infectious prion protein. They
remain in clinical phase for 2
2-3
3 weeks until they succumb to the disease. Graph A
shows the survival chart of the infected animal
animals.. In their brain they show extended
vacuolation as seen in H&E staining of the inferior culliculus (B) as well deposition
of prion protein (C) and activation of astroglial cells (D).
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BSB prion after digestion: GSDAAPAGAPVLVP

Diagram 14. Structure of the beta-sheet breaker super gene. We expect
that seven segments containing BSB (green) can be released after cleavage into
the extracellular space. PCS-T (purple) sequences are consensus sequences for
thrombin, a peptidase secreted by brain endothelial cells.

IV. Conclusions
The use of stem cells for human cell therapies opens a new window of hope
for regenerative medicine for individuals affected with a wide range of diseases like
neurodegenerative diseases, myocardial failure, stroke, traumatic brain injury and
many other others disorders.
Embryonic stem cells form part of the blastula and are able to differentiate to
all types of cells in the body. In vitro, ESC can be extracted and maintained in vitro
for an unlimited number of passages while maintaining their pluripotent capabilities.
Furthermore, ESC ban be differentiated in vitro to different cellular populations,
including adult stem cells like neural precursors or fully differentiated cells like
neurons. Neural Precursors have the potential to complete their developmental fate
when they are grafted being able to survive and integrate within the host neuronal
tissue. These advantages of neuronal stem cells position them as a good
biomaterial for the development of replacement therapies in order to regenerate lost
brain cells due to aging or neurodegenerative diseases. Besides, neuronal stem
cells have the potential to act positively over the host brain by paracrine action
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thereby stimulating the survival of existing neuronal cells, stimulation of
neurogenesis and synaptogenesis. To date many groups have shown the potential
of stem cells, however their use in clinical practice has been narrow due to the
limited source of human embryonic stem cells. Overcoming those obstacles, IPS
cell technology offers the possibility to generate ESC-like cells from somatic cells
like skin or blood cells. This offers the possibility to generate stem cells from adult
patients to then use them for regenerative therapies within the same patient without
the threat of immune rejection. Besides, thanks to the advances in molecular
biology, IPS cells could be treated to repair genetic defects and reinserted into the
same patient. Although the technology is promising, it must still be improved in
order to be safe in the clinical practice.
In this work we proposed to investigate if IPS cells could be generated from
animals resistant to prion diseases. We generated IPS cells from transgenic mice
lacking the prion protein, which we know is resistant to the toxic damage of prion
infection. Skin cells from those animals were culture in vitro and then transduced to
overexpress Oct-4, Sox-2, Myc-C and Klf-4. Transduced cells showed to be
different

in

morphology

and

developmental

capabilities.

They

expressed

pluripotency markers and were capable to form solid tumors and embryoid bodies.
In vitro those cells were differentiated to neural precursor cells that were able to
give raise to neurons in vitro. In preparation for the implantation of the neuronal
precursor cells in the brain of sick animals, we tested several protocols to trace the
cells by fluorescence. It is important to note that IPS cells were generated from the
skin of old animals (1 year old mice), indicating that the age of the animals is not a
limiting factor for reprogramming of prp-/- cells.
Next experiments include engrafting the neural precursors devoid of the prion
protein as well as wild type neural precursors in the experimental animals and
evaluating if the treatment extends the lifespan. In parallel, other experiments to do
(work which is currently in progress) include to engineering the cells to make them
release beta-sheet breakers and BDNF to induce the elimination of misfolded prions
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and to improve the survival and functional capabilities of the existing network,
respectively.
We expect that our studies could serve as proof of concept of the use of
neural precursors generated from fibroblasts-derived pluripotent cells of prion
affected patients. In theory, those cells could be engineered in the test tube to
decrease the expression of prion protein and be more resistant once engrafted in
the brain or peripheral tissue of the patient.
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